球囊闭塞经导管动脉化疗栓塞治疗常规经导管动脉化疗栓塞难治性肝细胞癌的安全性与有效性
单中心回顾性分析纳入60例常规TACE难治性肝细胞癌患者行球囊闭塞TACE,技术成功率与首次随访CT的m-RECIST影像学缓解率均为100%,主要并发症率6.7%,中位TTP 5.3个月;治疗残留病灶时B-TACE的TTP显著长于末次C-TACE(4.4 vs 2.7个月,p=0.013)。
要点
- 首次随访CT按m-RECIST评估,B-TACE的影像学缓解率达100%(完全缓解45例、部分缓解15例)。
- 治疗残留肝细胞癌时,B-TACE的中位TTP 4.4个月 vs 末次C-TACE 2.7个月(p=0.013)。
- BCLC C期与肿瘤多发是B-TACE后肿瘤进展的独立相关因素。
诊断标准与关键数值
- 影像学缓解定义为首次随访CT按m-RECIST达到完全缓解或部分缓解,B-TACE的缓解率为100%(完全缓解45例、部分缓解15例)。
- B-TACE的主要并发症率为6.7%(4/60)。
- B-TACE后中位TTP为5.3个月(95%CI 4.0-6.9个月)。
- 治疗残留肝细胞癌时,B-TACE的中位TTP 4.4个月(95%CI 3.2-6.9)vs 末次C-TACE 2.7个月(95%CI 2.3-4.4),p=0.013。
- BCLC C期与B-TACE后肿瘤进展相关(校正OR 4.448,95%CI 1.691-11.700,p=0.002);肿瘤多发与B-TACE后肿瘤进展相关(校正OR 2.746,95%CI 1.206-6.251,p=0.016)。
临床应用与阅片要点
- 原文结论为B-TACE对常规TACE难治性肝细胞癌安全有效,首次随访影像学缓解率达100%。
- 原文指出BCLC C期与肿瘤多发是B-TACE后TTP的独立相关因素。
- 原文要点指出肿瘤大小、肿瘤多发及肝动脉损伤是获得完全缓解的独立相关因素。
- 原文要点指出B-TACE后AST、ALT及总胆红素升高较末次C-TACE更明显,但首次随访时已恢复正常。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the safety and efficacy of balloon-occluded transcatheter arterial chemoembolization (B-TACE) for the treatment of HCC refractory to conventional TACE (C-TACE).
METHODS: This single-center retrospective analysis included 60 consecutive patients who underwent B-TACE (mean age, 61.4 years; male:female ratio, 4.5:1) for the treatment of residual viable (n = 40) or recurrent HCC (n = 20) refractory to C-TACE between November 2017 and November 2018. Technical success, radiologic response rate (proportion of the patients achieving complete response [CR] or partial response [PR] on first follow-up CT according to m-RECIST), major complication rate, and time to progression (TTP) were evaluated. The TTP of B-TACE was also compared with that of the last C-TACE. Factors associated with achieving CR and TTP were explored.
RESULTS: B-TACE resulted in 100% technical success and radiologic response rate (CR in 45 and PR in 15 patients). The major complication rate was 6.7% (4/60). The median TTP after B-TACE was 5.3 months (95% confidence interval [CI], 4.0-6.9 months). The TTP of B-TACE for treating residual HCC was significantly longer than that of the last C-TACE (median [95% CI], 4.4 [3.2-6.9] vs. 2.7 [2.3-4.4] months; p = 0.013). BCLC stage C (adjusted OR, 4.448; 95% CI, 1.691-11.700; p = 0.002) and multiplicity of HCC (adjusted OR, 2.746; 95% CI, 1.206-6.251; p = 0.016) were significantly associated with tumor progression after B-TACE.
CONCLUSIONS: B-TACE is safe and effective for the treatment of HCC refractory to C-TACE. BCLC stage C and multiplicity of HCC were independent factors associated with TTP after B-TACE.
KEY POINTS: • B-TACE for the treatment of HCC refractory to C-TACE showed a 100% radiologic response at first follow-up and a significantly longer TTP than the last C-TACE when treating residual tumor. • The major complication rate after B-TACE was 6.7%. Although AST, ALT, and total bilirubin increase were more profound in B-TACE than in the last C-TACE, these were normalized at the first follow-up. • Tumor size, multiplicity of HCC, and hepatic arterial injury were independent factors associated with achieving a complete response. BCLC stage C and multiplicity of HCC were significantly associated with TTP after B-TACE.
引用
- Kim PH, Gwon DI, Kim JW, et al. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol. 2020. PMID: 32409860. doi:10.1007/s00330-020-06911-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。